Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-10-07 06:00 EST

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

OCSOculis2026-10-01 06:00 EST

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

OCSOculis2026-09-30 21:32 EST

Oculis Announces Resignation of Lionel Carnot from Board of Directors

OCSOculis2026-09-17 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-24 08:00 EST

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Stock data

Close: 8.72 USD
Market cap: 742.17M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Related news

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Oculis